ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Amsacrine (United States and Canada: Not available): Drug information

Amsacrine (United States and Canada: Not available): Drug information
(For additional information see "Amsacrine (United States and Canada: Not available): Patient drug information")

For abbreviations, symbols, and age group definitions used in Lexicomp (show table)
Pharmacologic Category
  • Antineoplastic Agent, Miscellaneous
Dosing: Adult
Acute leukemia

Acute leukemia: IV:

Induction: 75 to 125 mg/m2/day for 5 days every 3 to 4 weeks (125 mg/m2/day is preferred; two courses may be necessary to achieve induction; increase dose by 20% in second and subsequent cycles if marrow hypoplasia not achieved and in absence of significant toxicity in previous course.)

Maintenance: Once remission has been achieved, maintenance dose should be ~50% of induction dose, administered every 4 to 8 weeks, depending on blood cell counts and marrow recovery

Acute myeloid leukemia

Acute myeloid leukemia (off-label dosing): IV: 120 mg/m2 over 60 minutes on days 3, 5, and 7 of induction cycle 2 (in combination with cytarabine) (Ref) or 120 mg/m2 over 60 minutes on days 4, 5, and 6 of induction cycle 2 (in combination with cytarabine ± G-CSF) (Ref)

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Adult

BUN >20 mg/dL and/or serum creatinine >1.2 mg/dL: Dosage reduction is recommended; however, there are no specific adjustments provided in the manufacturer's labeling. The following adjustments have been reported:

Serum creatinine 1.2 to 1.8 mg/dL: No dosage adjustment necessary (Ref).

Serum creatinine >2 to 3 mg/dL or oliguric patients: Reduce initial dose by 30% to 40%; may increase subsequent dose based on assessment of toxicity (Ref).

Dosing: Hepatic Impairment: Adult

Bilirubin >2 mg/dL: Dosage reduction is recommended; however, there are no specific adjustments provided in the manufacturer’s labeling. The following adjustments have been reported:

Bilirubin >2 mg/dL: Reduce initial dose by 30% to 40%; may increase subsequent dose based on assessment of toxicity (Ref).

Bilirubin >2 mg/dL (>34 micromol/L): Reduce dose by at least 50% (Ref).

Dosing: Obesity: Adult

American Society of Clinical Oncology guidelines for appropriate systemic therapy dosing in adults with cancer with a BMI ≥30 kg/m2 : Utilize patient's actual body weight (full weight) for calculation of BSA- or weight-based dosing; manage regimen-related toxicities in the same manner as for patients with a BMI <30 kg/m2; if a dose reduction is utilized due to toxicity, may consider resumption of full weight-based dosing (or previously tolerated dose level) with subsequent cycles only if dose escalations are allowed in the prescribing information, if contributing underlying factors (eg, hepatic or kidney impairment) are sufficiently resolved, AND if performance status has markedly improved or is considered adequate (Ref).

Dosing: Adjustment for Toxicity: Adult

Consider decreasing dose by 20% if life-threatening infection or hemorrhage occurred in previous cycle; delay second and subsequent cycles until recovery from myelosuppression or for evidence of leukemic infiltrate.

Dosing: Older Adult

Refer to adult dosing.

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Frequency not always defined.

Cardiovascular: Atrial fibrillation, atrial tachycardia, bradycardia, cardiac failure (rare), cardiomyopathy (rare), cardiorespiratory arrest, ECG changes (prolonged QT interval on ECG, nonspecific ST or T wave changes on ECG), hypotension, phlebitis, reduced ejection fraction, sinus tachycardia, tachycardia, ventricular arrhythmia, ventricular fibrillation, ventricular premature contractions, ventricular tachyarrhythmia

Central nervous system: Confusion, dizziness, emotional lability, headache, hypoesthesia, lethargy, paresthesia, seizure

Dermatologic: Allergic dermatitis, alopecia, dermatological reaction, maculopapular rash, urticaria

Endocrine & metabolic: Weight changes

Gastrointestinal: Abdominal pain (>10%), diarrhea (>10%), nausea (>10%), stomatitis (>10%), vomiting (>10%), anorexia, dysphagia, gingival hemorrhage, gingivitis, hematemesis

Genitourinary: Perirectal abscess (>10%), hematuria, proteinuria, urine abnormality (orange-red discoloration)

Hematologic & oncologic: Bone marrow depression (>10%), leukopenia (>10%; nadir: 11-13 days; recovery: days 17-25), anemia, granulocytopenia, hemorrhage, pancytopenia, purpura, purpuric rash, thrombocytopenia

Hepatic: Hepatic failure (progressive), hepatic insufficiency, hepatitis, hepatotoxicity, increased serum alkaline phosphatase, increased serum AST, increased serum bilirubin, jaundice

Hypersensitivity: Hypersensitivity reaction

Infection: Infection

Local: Inflammation at injection site

Neuromuscular & skeletal: Musculoskeletal pain, weakness

Renal: Increased blood urea nitrogen, increased serum creatinine, renal failure

Respiratory: Dyspnea

Miscellaneous: Fever

Contraindications

Hypersensitivity to amsacrine, acridine derivatives (eg, acriflavine), or any component of the formulation; preexisting drug-induced or radiation therapy-induced bone marrow suppression

Warnings/Precautions

Concerns related to adverse effects:

• Bone marrow suppression: Amsacrine is a potent bone marrow suppressant; effects may be prolonged and may require intensive supportive therapy. Monitor complete blood cell count (CBC) with differential frequently during induction therapy and for 2 to 3 weeks following amsacrine administration. Leukopenia is generally transient. The WBC nadir usually occurs at 11 to 13 days after treatment; recovery usually occurs by days 17 to 25. Anemia and thrombocytopenia may also occur. Monitor for infection (due to neutropenia) and bleeding (due to thrombocytopenia). Hematologic toxicity may require dose reduction, therapy interruption and/or treatment delay. Doses higher than recommended may result in more severe and prolonged marrow suppression. Monitor bone marrow as clinically necessary.

• Cardiovascular effects: Cases of acute arrhythmia have been reported; heart failure, bradycardia, and tachycardia have been observed. Risk factors for arrhythmia may include hypokalemia and prior anthracycline therapy. Correct fluid and electrolyte imbalance prior to treatment initiation. Serum potassium should be >4 mEq/L prior to administration (Arlin 1988). Monitor ECG during and after administration.

• Extravasation: Irritant with vesicant-like properties; ensure proper needle or catheter placement prior to and during infusion. Avoid extravasation. Extravasation may result in severe irritation or necrosis.

• Tumor lysis syndrome: Tumor lysis syndrome may occur; adequate hydration and prophylactic uric acid reduction should be considered prior to or during treatment; monitor closely.

Disease-related concerns:

• Hepatic impairment: Hepatic metabolism and biliary excretion are major routes of amsacrine elimination. Toxicities may be increased in patients with significant hepatic impairment (bilirubin >2 mg/dL); dosage reductions are recommended. Monitor hepatic function prior to and during treatment.

• Renal impairment: Toxicities may be increased in patients with significant renal impairment (BUN >20 mg/dL; serum creatinine >1.2 mg/dL); dosage reductions are recommended. Monitor renal function prior to and during treatment.

Concurrent drug therapy issues:

• Vaccinations: Avoid vaccination with live virus vaccines during treatment.

Dosage form specific issues:

• AMSA PD: The manufacturer reports a low risk of microbial contamination and infection with AMSA PD injection (50 mg/mL); risk may be further minimized with the use of Sartorius sterile filters (Minisart SRP [PTFE] 0.2 micrometer, 15 mm; provided by the manufacturer) prior to transferring AMSA PD to the diluent. Monitor for signs/symptoms of infection during therapy (Health Canada 2014).

Product Availability

Not available in the US

Generic Equivalent Available: US

Yes

Administration: Adult

IV: Infuse over 60 to 90 minutes.

Amsacrine contains N,N-dimethylacetamide, which may be incompatible with some closed system transfer devices (CSTDs); the plastic components of some CSTDs may dissolve and may result in subsequent leakage and potential infusion of dissolved plastic into the patient (Ref). Refer to the specific CSTD device manufacturer for compatibility data.

Irritant with vesicant-like properties; ensure proper needle or catheter placement prior to and during infusion; avoid extravasation.

Extravasation management: If extravasation occurs, stop infusion immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do NOT flush the line); remove needle/cannula; elevate extremity.

Hazardous Drugs Handling Considerations

Hazardous agent (NIOSH 2016 [group 1]).

Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations and institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).

Use: Labeled Indications

Note: Not approved in the US.

Acute leukemia: Remission induction in refractory acute leukemia in adults

Medication Safety Issues
Other safety concerns:

A solvent in amsacrine, N,N-dimethylacetamide, may be incompatible with some closed system transfer devices (CSTDs) used for preparing injectable antineoplastics. The plastic components of some CSTDs may dissolve and may result in subsequent leakage and potential infusion of dissolved plastic into the patient (ISMP [Smetzer 2015]). Refer to the specific CSTD device manufacturer for compatibility data.

Metabolism/Transport Effects

None known.

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.

5-Aminosalicylic Acid Derivatives: May enhance the myelosuppressive effect of Myelosuppressive Agents. Risk C: Monitor therapy

Abrocitinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy). Risk X: Avoid combination

Antithymocyte Globulin (Equine): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of cytotoxic chemotherapy is reduced. Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. Risk C: Monitor therapy

Baricitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Baricitinib. Risk X: Avoid combination

BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). Risk X: Avoid combination

BCG Products: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of BCG Products. Risk X: Avoid combination

Brincidofovir: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Brincidofovir. Risk C: Monitor therapy

Brivudine: May enhance the adverse/toxic effect of Immunosuppressants (Cytotoxic Chemotherapy). Risk X: Avoid combination

Chikungunya Vaccine (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Chikungunya Vaccine (Live). Risk X: Avoid combination

Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents. Risk C: Monitor therapy

Chloramphenicol (Systemic): Myelosuppressive Agents may enhance the myelosuppressive effect of Chloramphenicol (Systemic). Risk X: Avoid combination

Cladribine: May enhance the myelosuppressive effect of Myelosuppressive Agents. Risk X: Avoid combination

Cladribine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Cladribine. Risk X: Avoid combination

CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. Risk C: Monitor therapy

Coccidioides immitis Skin Test: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the diagnostic effect of Coccidioides immitis Skin Test. Management: Consider discontinuing cytotoxic chemotherapy several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results. Risk D: Consider therapy modification

COVID-19 Vaccine (Adenovirus Vector): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Adenovirus Vector). Management: Administer a 2nd dose using an mRNA COVID-19 vaccine (at least 4 weeks after the primary vaccine dose) and a bivalent booster dose (at least 2 months after the additional mRNA dose or any other boosters). Risk D: Consider therapy modification

COVID-19 Vaccine (Inactivated Virus): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Inactivated Virus). Risk C: Monitor therapy

COVID-19 Vaccine (mRNA): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (mRNA). Management: Give a 3-dose primary series for all patients aged 6 months and older taking immunosuppressive medications or therapies. Booster doses are recommended for certain age groups. See CDC guidance for details. Risk D: Consider therapy modification

COVID-19 Vaccine (Subunit): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Subunit). Risk C: Monitor therapy

COVID-19 Vaccine (Virus-like Particles): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Virus-like Particles). Risk C: Monitor therapy

Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. Management: Avoid the concomitant use of deferiprone and myelosuppressive agents whenever possible. If this combination cannot be avoided, monitor the absolute neutrophil count more closely. Risk D: Consider therapy modification

Dengue Tetravalent Vaccine (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live). Risk X: Avoid combination

Denosumab: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy). Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and cytotoxic chemotherapy. If combined, monitor patients for signs/symptoms of serious infections. Risk D: Consider therapy modification

Deucravacitinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy). Risk X: Avoid combination

Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased Risk X: Avoid combination

Etrasimod: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy). Risk X: Avoid combination

Fexinidazole: Myelosuppressive Agents may enhance the myelosuppressive effect of Fexinidazole. Risk X: Avoid combination

Filgotinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy). Risk X: Avoid combination

Inebilizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Inebilizumab. Risk C: Monitor therapy

Influenza Virus Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Influenza Virus Vaccines. Management: Administer influenza vaccines at least 2 weeks prior to initiating chemotherapy if possible. If vaccination occurs less than 2 weeks prior to or during chemotherapy, revaccinate at least 3 months after therapy discontinued if immune competence restored. Risk D: Consider therapy modification

Leflunomide: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Leflunomide. Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents, such as cytotoxic chemotherapy. Risk D: Consider therapy modification

Lenograstim: Antineoplastic Agents may diminish the therapeutic effect of Lenograstim. Management: Avoid the use of lenograstim 24 hours before until 24 hours after the completion of myelosuppressive cytotoxic chemotherapy. Risk D: Consider therapy modification

Lipegfilgrastim: Antineoplastic Agents may diminish the therapeutic effect of Lipegfilgrastim. Management: Avoid concomitant use of lipegfilgrastim and myelosuppressive cytotoxic chemotherapy. Lipegfilgrastim should be administered at least 24 hours after the completion of myelosuppressive cytotoxic chemotherapy. Risk D: Consider therapy modification

Mumps- Rubella- or Varicella-Containing Live Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. Risk X: Avoid combination

Nadofaragene Firadenovec: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. Risk X: Avoid combination

Natalizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Natalizumab. Risk X: Avoid combination

Ocrelizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ocrelizumab. Risk C: Monitor therapy

Ofatumumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ofatumumab. Risk C: Monitor therapy

Olaparib: Myelosuppressive Agents may enhance the myelosuppressive effect of Olaparib. Risk C: Monitor therapy

Palifermin: May enhance the adverse/toxic effect of Antineoplastic Agents. Specifically, the duration and severity of oral mucositis may be increased. Management: Do not administer palifermin within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy. Risk D: Consider therapy modification

Pidotimod: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Pidotimod. Risk C: Monitor therapy

Pimecrolimus: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy). Risk X: Avoid combination

Pneumococcal Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Pneumococcal Vaccines. Risk C: Monitor therapy

Poliovirus Vaccine (Live/Trivalent/Oral): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Risk X: Avoid combination

Polymethylmethacrylate: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the potential for allergic or hypersensitivity reactions to Polymethylmethacrylate. Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration. Risk D: Consider therapy modification

Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents. Risk C: Monitor therapy

Rabies Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Rabies Vaccine. Management: Complete rabies vaccination at least 2 weeks before initiation of immunosuppressant therapy if possible. If combined, check for rabies antibody titers, and if vaccination is for post exposure prophylaxis, administer a 5th dose of the vaccine. Risk D: Consider therapy modification

Ritlecitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ritlecitinib. Risk X: Avoid combination

Ropeginterferon Alfa-2b: Myelosuppressive Agents may enhance the myelosuppressive effect of Ropeginterferon Alfa-2b. Management: Avoid coadministration of ropeginterferon alfa-2b and other myelosuppressive agents. If this combination cannot be avoided, monitor patients for excessive myelosuppressive effects. Risk D: Consider therapy modification

Ruxolitinib (Topical): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ruxolitinib (Topical). Risk X: Avoid combination

Sipuleucel-T: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Sipuleucel-T. Management: Consider reducing the dose or discontinuing the use of immunosuppressants, such as cytotoxic chemotherapy, prior to initiating sipuleucel-T therapy. Risk D: Consider therapy modification

Sphingosine 1-Phosphate (S1P) Receptor Modulator: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy). Risk C: Monitor therapy

Tacrolimus (Topical): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Tacrolimus (Topical). Risk X: Avoid combination

Talimogene Laherparepvec: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. Risk X: Avoid combination

Tertomotide: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Tertomotide. Risk X: Avoid combination

Tofacitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Tofacitinib. Risk X: Avoid combination

Typhoid Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Typhoid Vaccine. Risk X: Avoid combination

Ublituximab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ublituximab. Risk C: Monitor therapy

Upadacitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Upadacitinib. Risk X: Avoid combination

Vaccines (Inactivated/Non-Replicating): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating). Management: Give inactivated vaccines at least 2 weeks prior to initiation of chemotherapy when possible. Patients vaccinated less than 14 days before initiating or during chemotherapy should be revaccinated at least 3 months after therapy is complete. Risk D: Consider therapy modification

Vaccines (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Vaccines (Live) may diminish the therapeutic effect of Immunosuppressants (Cytotoxic Chemotherapy). Risk X: Avoid combination

Yellow Fever Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Yellow Fever Vaccine. Risk X: Avoid combination

Reproductive Considerations

Females of reproductive potential should avoid becoming pregnant while receiving treatment.

Pregnancy Considerations

Animal reproduction studies have not been conducted.

Breastfeeding Considerations

It is not known if amsacrine is present in breast milk. Breastfeeding should be discontinued prior to amsacrine treatment.

Monitoring Parameters

CBC with differential (frequently during induction and for 2 to 3 weeks after), electrolytes including potassium (prior to each dose), hepatic and renal function (regularly); bone marrow studies (periodically); ECG (during and after administration). Monitor for infection, bleeding, monitor fluid status, monitor for signs/symptoms of tumor lysis syndrome; monitor infusion site during infusion.

The American Society of Clinical Oncology hepatitis B virus (HBV) screening and management provisional clinical opinion (ASCO [Hwang 2020]) recommends HBV screening with hepatitis B surface antigen, hepatitis B core antibody, total Ig or IgG, and antibody to hepatitis B surface antigen prior to beginning (or at the beginning of) systemic anticancer therapy; do not delay treatment for screening/results. Detection of chronic or past HBV infection requires a risk assessment to determine antiviral prophylaxis requirements, monitoring, and follow-up.

Mechanism of Action

Amsacrine has been shown to inhibit topoisomerase II activity and DNA synthesis. Amsacrine may bind and intercalate into DNA, resulting in DNA double-strand breaks and cell cycle arrest (at the S/G2 phase).

Pharmacokinetics (Adult Data Unless Noted)

Protein binding: 85% to 95% (Hall 1983).

Metabolism: Hepatic (primarily).

Half-life elimination: Terminal: Mean 7.4 hours; range: 6 to 10 hours (Hall 1983).

Excretion: Bile (primarily); urine (35%; 20% as unchanged drug).

Brand Names: International
International Brand Names by Country
For country code abbreviations (show table)

  • (AU) Australia: Amsidyl;
  • (BG) Bulgaria: Amsidine;
  • (CH) Switzerland: Amsidyl;
  • (CZ) Czech Republic: Amsidyl;
  • (EE) Estonia: Amcidine | Amsidine;
  • (ES) Spain: Amsacrina;
  • (FI) Finland: Amekrin;
  • (GB) United Kingdom: Amsidine | Trav amsidine;
  • (IT) Italy: Amsadina;
  • (KR) Korea, Republic of: Amsidine;
  • (NL) Netherlands: Amsidine;
  • (NO) Norway: Amekrin | Amsidine;
  • (NZ) New Zealand: Amsidyl;
  • (PL) Poland: Amsidyl;
  • (SE) Sweden: Amekrin;
  • (SK) Slovakia: Amsidyl
  1. <800> Hazardous Drugs–Handling in Healthcare Settings. United States Pharmacopeia and National Formulary (USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.
  2. AMSA PD (amsacrine) [product monograph]. Westmount, QC, Canada: Erfa Canada Inc; August 2005.
  3. Arlin ZA, Feldman, E. Kempin S, et al. Amsacrine with high-dose cytarabine is highly effective therapy for refractory and relapsed acute lymphoblastic leukemia in adults. Blood. 1988;72(2):433-435. [PubMed 3165293]
  4. Griggs JJ, Bohlke K, Balaban EP, et al. Appropriate systemic therapy dosing for obese adult patients with cancer: ASCO guideline update. J Clin Oncol. 2021;39(18):2037-2048. doi:10.1200/JCO.21.00471 [PubMed 33939491]
  5. Hall SW, Friedman J, Legha SS, et al. Human pharmacokinetics of a new acridine derivative, 4'-(9-Acridinylamino)methanesulfon-m-anisidide (NSC 249992). Cancer Res. 1983;43(7):3422-3426. [PubMed 6687834]
  6. Health Canada Advisory RA-41245. Available at :http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2014/41245a-eng.php. August 29, 2014.
  7. Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. J Clin Oncol. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757 [PubMed 32716741]
  8. Koren G, Beatty K, Seto A, et al. The effects of impaired liver function on the elimination of antineoplastic agents. Ann Pharmacother. 1992;26(3):363-371. [PubMed 1554959]
  9. Löwenberg B, Pabst T, Vellenga E, et al; Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) Collaborative Group. Cytarabine dose for acute myeloid leukemia. N Engl J Med. 2011;364(11):1027-1036. doi: 10.1056/NEJMoa1010222. [PubMed 21410371]
  10. Löwenberg B, van Putten W, Theobald M, et al; Dutch-Belgian Hemato-Oncology Cooperative Group; Swiss Group for Clinical Cancer Research. Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. N Engl J Med. 2003;349(8):743-752. [PubMed 12930926]
  11. Pérez Fidalgo JA, García Fabregat L, Cervantes A, et al. Management of chemotherapy extravasation: ESMO-EONS clinical practice guidelines. Ann Oncol. 2012;23(suppl 7):167-173. [PubMed 22997449]
  12. Schulmeister L. Extravasation management: clinical update. Semin Oncol Nurs. 2011; 27(1):82-90. [PubMed 21255716]
  13. Smetzer J, Cohen M, eds. Update on bendamustine and CSTDs. ISMP Medication Safety Alert! Acute Care Edition. 2015;20(5):2-3.
  14. US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. https://www.cdc.gov/niosh/docs/2016-161/default.html. Updated September 2016. Accessed February 5, 2020.
Topic 9343 Version 204.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟